Gsa Capital Partners LLP I Mab Transaction History

Gsa Capital Partners LLP

$1.19 Billion
Q1 2024

A detailed history of Gsa Capital Partners LLP transactions in I Mab stock. As of the latest transaction made, Gsa Capital Partners LLP holds 432,621 shares of IMAB stock, worth $648,931. This represents 0.07% of its overall portfolio holdings.

Number of Shares

432,621

Previous 538,119 19.6%

Holding current value

$648,931

Previous $1.02 Million 21.33%

% of portfolio

0.07%

Previous 0.09%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	SELL	$1.54 - $2.37 $162,466 - $250,030	-105,498 Reduced 19.6%	432,621 $804,000
Q4 2023 Feb 16, 2024	BUY	$1.21 - $1.9 $414,513 - $650,888	342,573 Added 175.19%	538,119 $1.02 Million
Q3 2023 Nov 15, 2023	BUY	$1.18 - $3.06 $78,068 - $202,449	66,160 Added 51.13%	195,546 $258,000
Q2 2023 Aug 14, 2023	BUY	$2.95 - $3.85 $96,851 - $126,399	32,831 Added 34.0%	129,386 $386,000
Q1 2023 May 12, 2023	SELL	$3.08 - $7.39 $372,236 - $893,125	-120,856 Reduced 55.59%	96,555 $334,000

Q4 2022 Feb 13, 2023	BUY	$3.22 - $4.86 $611,838 - $923,458	190,012 Added 693.5%	217,411 $909,000
Q3 2022 Nov 14, 2022	BUY	$4.01 - $12.34 $36,908 - $113,577	9,204 Added 50.59%	27,399 $110,000
Q2 2022 Aug 09, 2022	BUY	$8.27 - $18.43 $4,019 - $8,956	486 Added 2.74%	18,195 $206,000
Q1 2022 May 11, 2022	BUY	$12.54 - $46.93 $222,070 - $831,083	17,709 New	17,709 $288,000
Q3 2021 Nov 12, 2021	SELL	$57.18 - $84.43 $499,238 - $737,158	-8,731 Closed	0 $0
Q2 2021 Aug 05, 2021	BUY	$47.86 - $83.95 $417,865 - $732,967	8,731 New	8,731 $733,000

Others Institutions Holding IMAB

# of Institutions

Shares Held

16M

Call Options Held

11.9K

Put Options Held

3.5K

View Full List

About I-Mab

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $125M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

More about IMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Account

Gsa Capital Partners LLP I Mab Transaction History